Toll-like receptors in the pathogenesis of human B cell malignancies

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Isaza Correa, Johana M ^a   Liang, Zheng ^a   Van Den Berg, Anke ^a   Diepstra, Arjan ^a   Visser, Lydia ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GROWTH; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; CELL TRANSFORMATION; DISEASE COURSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR ESCAPE;

B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; LYMPHOMA, B-CELL; TOLL-LIKE RECEPTORS; TUMOR ESCAPE;

EID: 84906931498     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0057-5     Document Type: Review

References (69)

1. Toll-like receptor signaling. S Akira, K Takeda, Nat Rev Immunol 2004 4 499 511 10.1038/nri1391 15229469
2. Cancer cells expressing toll-like receptors and the tumor microenvironment. Y Sato, Y Goto, N Narita, DS Hoon, Cancer Microenviron 2009 2 Suppl 1 205 214 10.1007/s12307-009-0022-y 19685283
3. Toll-like receptor signaling in cell proliferation and survival. X Li, S Jiang, RI Tapping, Cytokine 2010 49 1 9 10.1016/j.cyto.2009.08.010 19775907
4. Toll-like receptors: lessons to learn from normal and malignant human B cells. D Chiron, I Bekeredjian-Ding, C Pellat-Deceunynck, R Bataille, G Jego, Blood 2008 112 2205 2213 10.1182/blood-2008-02-140673 18591383
5. Quantitative expression of toll-like receptor 1-10 mRNA in Cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG Oligodeoxynucleotides. V Hornung, S Rothenfusser, S Britsch, A Krug, B Jahrsdörfer, T Giese, S Endres, G Hartmann, J Immunol 2002 168 4531 4537 10.4049/jimmunol.168.9.4531 11970999
6. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. NL Bernasconi, N Onai, A Lanzavecchia, Blood 2003 101 4500 4504 10.1182/blood-2002-11-3569 12560217
7. A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. A Mansson, M Adner, U Hockerfelt, LO Cardell, J Immunol 2006 118 539 548
8. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. J Bohnhorst, T Rasmussen, SH Moen, M Fløttum, L Knudsen, M Børset, T Espevik, A Sundan, Leukemia 2006 20 1138 1144 10.1038/sj.leu.2404225 16617319
9. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. E Bourke, D Bosisio, J Golay, N Polentarutti, A Mantovani, Blood 2003 102 956 963 10.1182/blood-2002-11-3355 12689944
10. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. IB Bekeredjian-Ding, M Wagner, V Hornung, T Giese, M Schnurr, S Endres, G Hartmann, J Immunol 2005 174 4043 4050 10.4049/jimmunol.174.7.4043 15778362
11. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naïve and memory B cell subsets to produce cytokines, chemokines and hematopoietic growth factors. S Agrawal, S Gupta, J Clin Immunol 2011 31 89 98 10.1007/s10875-010-9456-8 20821041
12. Toll-like receptor 2-mediated human B cell differentiation. LM Ganley-Leal, X Liu, LM Wetzler, Clin Immunol 2006 120 272 284 10.1016/j.clim.2006.04.571 16766226
13. Toll-like receptor 7 controls the anti-retroviral germinal center response. EP Browne, PLoS Pathog 2011 7 1002293 10.1371/journal.ppat.1002293 21998589
14. IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Bessa, M Kopf, MF Bachmann, J Immunol 2010 184 4615 4619 10.4049/jimmunol.0903949 20368279
15. Mitogen- and IL-4-regulated expression of germ-line Ig gamma 2b transcripts: evidence for directed heavy chain class switching. S Lutzker, P Rothman, R Pollock, R Coffman, FW Alt, Cell 1988 53 177 184 10.1016/0092-8674(88)90379-0 2834063
16. CpG DNA redirects class-switching towards "Th1-like" Ig isotype production via TLR9 and MYD88. L Lin, AJ Gerth, SL Peng, Eur J Immunol 2004 34 1483 1487 10.1002/eji.200324736 15114682
17. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. CR Ruprecht, A Lanzavecchia, Eur J Immunol 2006 36 810 816 10.1002/eji.200535744 16541472
18. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. B He, X Qiao, A Cerutti, J Immunol 2004 173 4479 4491 10.4049/jimmunol.173.7.4479 15383579
19. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. W Xu, PA Santini, AJ Matthews, A Chiu, A Plebani, B He, K Chen, A Cerutti, J Immunol 2008 181 276 287 10.4049/jimmunol.181.1.276 18566393
20. CD40 signaling synergizes with TLR-2 in the BCR independent activation of resting B cells. S Jain, SB Chodisetti, JN Agrewala, PLoS One 2011 6 20651 10.1371/journal.pone.0020651 21674065
21. TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. A Aranburu, S Ceccarelli, E Giorda, R Lasorella, G Ballatore, R Carsetti, J Immunol 2010 185 7293 7301 10.4049/jimmunol.1002722 21078901
22. Control of B-cell responses by Toll-like receptors. C Pasare, R Medzhitov, Nature 2005 438 364 368 10.1038/nature04267 16292312
23. Programming the magnitude and persistence of antibody responses with innate immunity. SP Kasturi, I Skountzou, RA Albrecht, D Koutsonanos, T Hua, HI Nakaya, R Ravindran, S Stewart, M Alam, M Kwissa, F Villinger, N Murthy, J Steel, J Jacob, RJ Hogan, A Garcia-Sastre, R Compans, B Pulendran, Nature 2011 470 543 550 10.1038/nature09737 21350488
24. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. J Eckl-Dorna, FD Batista, Blood 2009 113 3969 3977 10.1182/blood-2008-10-185421 19144984
25. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. B Hou, P Saudan, G Ott, ML Wheeler, M Li, L Kuzmich, LM Lee, RL Coffman, MF Bachmann, AL DeFranco, Immunity 2011 34 375 384 10.1016/j.immuni.2011.01.011 21353603
26. TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presentation. W Jiang, MM Lederman, CV Harding, B Rodriguez, RJ Mohner, SF Sieg, Eur J Immunol 2007 37 2205 2213 10.1002/eji.200636984 17621369
27. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. F Capolunghi, S Cascioli, E Giorda, MM Rosado, A Plebani, C Auriti, G Seganti, R Zuntini, S Ferrari, M Cagliuso, I Quinti, R Carsetti, J Immunol 2008 180 800 808 10.4049/jimmunol.180.2.800 18178818
28. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. G Jego, R Bataille, A Geffroy-Luseau, G Descamps, C Pellat-Deceunynck, Leukemia 2006 20 1130 1137 10.1038/sj.leu.2404226 16628189
29. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Y Xu, Y Zhao, H Huang, G Chen, X Wu, Y Wang, W Chang, Z Zhu, Y Feng, D Wu, Br J Haematol 2010 150 543 553 10.1111/j.1365-2141.2010.08284.x 20629663
30. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. B Jahrsdorfer, L Mühlenhoff, SE Blackwell, M Wagner, H Poeck, E Hartmann, R Jox, T Giese, B Emmerich, S Endres, GJ Weiner, G Hartmann, Clin Cancer Res 2005 11 1490 1499 10.1158/1078-0432.CCR-04-1890 15746051
31. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. DE Spaner, Y Shi, D White, J Mena, C Hammond, J Tomic, L He, MA Tomai, RL Miller, J Booth, L Radvanyi, Leukemia 2006 20 286 295 10.1038/sj.leu.2404061 16341037
32. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. M Muzio, C Scielzo, MT Bertilaccio, M Frenquelli, P Ghia, F Caligaris-Cappio, Br J Haematol 2008 144 507 516 10.1111/j.1365-2141.2008.07475.x 19036098
33. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. SL Corthals, K Wynne, K She, H Shimizu, D Curman, K Garbutt, GS Reid, Br J Haematol 2005 132 452 458
34. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. M Henault, LN Lee, GF Evans, SH Zuckerman, J Immunol Methods 2005 300 93 99 10.1016/j.jim.2005.02.012 15894327
35. Gastric extranodal marginal zone B-cell lymphomas of MALT type exclusively express Toll-like receptor 4 in contrast to other lymphomas infiltrating the stomach. P Adam, B Schmausser, M Göbeler-Kolve, HK Müller-Hermelink, M Eck, Ann Oncol 2008 19 566 569 10.1093/annonc/mdm485 18042837
36. Toll-like receptor-4 signaling in mantle cell lymphoma: Effects on tumor growth and immune evasion. L Wang, Y Zhao, J Qian, L Sun, Y Lu, H Li, Y Li, J Yang, Z Cai, Q Yi, Cancer 2013 119 782 791 10.1002/cncr.27792 22915070
37. Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. TJ Smith, K Yamamoto, M Kurata, A Yukimori, S Suzuki, S Umeda, E Sugawara, Y Kojima, M Sawabe, Y Nakagawa, K Suzuki, JTB Crawley, M Kitagawa, Exp Mol Pathol 2010 89 284 290 10.1016/j.yexmp.2010.08.003 20800061
38. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. MP Purdue, Q Lan, SS Wang, A Kricker, I Menashe, TZ Zheng, P Hartge, AE Grulich, Y Zhang, LM Morton, CM Vajdic, TR Holford, RK Severson, BP Leaderer, JR Cerhan, M Yeager, W Cozen, K Jacobs, S Davis, N Rothman, SJ Chanock, N Chatterjee, BK Armstrong, Carcinogenesis 2009 30 275 281 10.1093/carcin/bgn262 19029192
39. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. A Nieters, L Beckmann, E Deeg, N Becker, Gene Immun 2006 7 615 624 10.1038/sj.gene.6364337
40. Polymorphisms and haplotypes in TLR9 and MyD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study. V Mollaki, T Georgiadis, A Tassidou, M Ioannou, Z Daniil, A Koutsoukera, AP Papathanassiou, E Zintzaras, G Vassilopoulos, J Hum Genet 2009 54 655 659 10.1038/jhg.2009.90 19745833
41. Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammatory pathway genes. CM Monroy, AC Cortes, MS Lopez, AM D'Amelio, CJ Etzel, A Younes, SS Strom, RA El-Zein, Mol Carcinogen 2011 50 36 46 10.1002/mc.20688
42. Oncogenically active MYD88 mutations in human lymphoma. VN Ngo, RM Young, R Schmitz, S Jhavar, W Xiao, KH Lim, H Kohlhammer, W Xu, Y Yang, H Zhao, AL Shaffer, P Romesser, G Wright, J Powell, A Rosenwald, HK Muller-Hermelink, G Ott, RD Gascoyne, JM Connors, LM Rimsza, E Campo, ES Jaffe, J Delabie, EB Smeland, RI Fisher, RM Braziel, RR Tubbs, JR Cook, DD Weisenburger, WC Chan, LM Staudt, Nature 2011 470 115 119 10.1038/nature09671 21179087
43. MYD88 L265P somatic mutation in Waldenström's macoglobulinemia. SP Treon, L Xu, G Yang, Y Zhou, X Liu, Y Cao, P Sheehy, RJ Manning, CJ Patterson, C Tripsas, L Arcaini, GS Pinkus, SJ Rodig, AR Sohani, NL Harris, JM Laramie, DA Skifter, SE Lincoln, ZR Hunter, N Engl J Med 2012 367 826 833 10.1056/NEJMoa1200710 22931316
44. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Q Yan, Y Huang, AJ Watkins, S Kocialkowski, N Zeng, RA Hamoudi, PG Isaacson, L de Leval, A Wotherspoon, MQ Du, Haematologica 2012 97 595 598 10.3324/haematol.2011.054080 22102703
45. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. XS Puente, M Pinyol, V Quesada, L Conde, GR Ordonez, N Villamor, G Escaramis, P Jares, S Bea, M Gonzales-Diaz, L Bassaganyas, T Baumann, M Juan, M Lopez-Guerra, D Colomer, JMC Tubio, C Lopez, A Navarro, C Tornador, M Aymerich, M Rozman, JM Hernandez, DA Puenta, JMP Freije, G Velasco, A Gutierrex-Fernandez, D Costa, A Carrio, S Guijarro, A Enjuanes, et al. Nature 2011 475 101105 10.1038/nature10113
46. Pathogenesis of human B cell lymphomas. AL Shaffer 3rd, RM Young, LM Staudt, Annu Rev Immunol 2012 30 565 610 10.1146/annurev-immunol-020711-075027 22224767
47. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. F Suarez, O Lortholary, O Hermine, M Lecuit, Blood 2006 107 3034 3044 10.1182/blood-2005-09-3679 16397126
48. Infectious agents and lymphoma development: molecular and clinical aspects. AJM Ferreri, I Ernberg, C Copie-Bergman, J Int Med 2009 265 421 438 10.1111/j.1365-2796.2009.02083.x
49. HIV-associated lymphoma. LD Kaplan, Best Pract Res Clin Haematol 2012 25 101 117 10.1016/j.beha.2012.01.001 22409827
50. EBV-associated lymphomas in adults. M Roschewski, WH Wilson, Best Pract Res Clin Hematol 2012 25 75 89 10.1016/j.beha.2012.01.005
51. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. A Neubauer, C Thiede, A Morgner, B Alpen, M Ritter, B Neubauer, T Wündisch, G Ehninger, M Stolte, E Bayerdörffer, J Natl Cancer Inst 1997 89 1350 1355 10.1093/jnci/89.18.1350 9308704
52. Regression of primary high-grade gastric B-cell lymphoma following Helicobacter pylori eradication. I Salam, D Durai, JK Murphy, B Sundaram, Eur J Gastroenterol Hepatol 2001 13 1375 1378 10.1097/00042737-200111000-00018 11692066
53. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. AC Wotherspoon, C Doglioni, TC Diss, L Pan, A Moschini, M de Boni, PG Isaacson, Lancet 1993 342 575 577 10.1016/0140-6736(93)91409-F 8102719
54. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. PG Longo, L Laurenti, S Gobessi, A Petlickovski, M Pelosi, P Chiusolo, S Sica, G Leone, DG Efremov, Leukemia 2007 21 110 120 10.1038/sj.leu.2404417 17024114
55. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. T Decker, F Schneller, T Sparwasser, T Tretter, GB Lipford, H Wagner, C Peschel, Blood 2000 95 999 1006 10648415
56. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. A Wolska, B Cebula-Obrzut, P Smolewski, T Robak, Leuk Lymphoma 2013 54 1268 1278 10.3109/10428194.2012.741233 23078646
57. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression shifts allogeneic T cells toward a Th1 response. GSD Reid, K She, L Terrett, MR Food, JD Trudeau, KR Schultz, Blood 2005 105 3641 3647 10.1182/blood-2004-06-2468 15650062
58. TLR-activated B cells suppress T cell mediated autoimmunity. V Lampropoulou, K Hoehlig, T Roch, P Neves, E Calderon Gomez, CH Sweenie, Y Hao, AA Freitas, U Steinhoff, SM Anderton, S Fillatreau, J Immunol 2008 180 4763 4773 10.4049/jimmunol.180.7.4763 18354200
59. TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. A Sayi, E Kohler, IM Toller, RA Flavell, W Müller, A Roers, A Müller, J Immunol 2011 186 878 890 10.4049/jimmunol.1002269 21149607
60. Increased level of both CD4 + FoxP3+ regulatory T cells and CD14 + HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. MK Brimnes, AJ Vangsted, LM Knudsen, P Gimsing, AO Gang, HE Johnsen, IM Svane, Scand J Immunol 2010 72 540 547 10.1111/j.1365-3083.2010.02463.x 21044128
61. Correlation of high numbers of intratumoral FoxP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. A Tzankov, C Meier, P Hirschmann, P Went, SA Pileri, S Dirnhofer, Hematologica 2008 93 193 200 10.3324/haematol.11702
62. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. H Fujii, JD Trudeau, DT Teachey, JD Fish, SA Grupp, KR Schultz, GSD Reid, Blood 2007 109 2008 2013 10.1182/blood-2006-02-002055 17068155
63. Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. AE Seif, DM Barrett, M Milone, VI Brown, SA Grupp, GSD Reid, Blood 2009 114 2459 2466 10.1182/blood-2009-02-203984 19636062
64. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. DE Spaner, RL Miller, J Mena, L Grossman, V Sorrenti, Y Shi, Leuk Lymphoma 2005 46 935 939 10.1080/10428190500054426 16019542
65. Combination therapy with CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-/β-inducible gene expression, without significant toxicity. JW Friedberg, H Kim, M McCauley, EM Hessel, P Sims, DC Fisher, LM Nadler, RL Coffman, AS Freedman, Blood 2005 105 489 495 10.1182/blood-2004-06-2156 15358617
66. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. JW Friedberg, JL Kelly, D Neuberg, DR Peterson, JL Kutok, R Salloum, T Brenn, DC Fisher, E Ronan, V Dalton, L Rich, D Marquis, P Sims, PG Rothberg, J Liesveld, RI Fisher, R Coffman, T Mosmann, AS Freedman, Br J Haematol 2009 146 282 291 10.1111/j.1365-2141.2009.07773.x 19519691
67. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. L Galluzzi, E Vacchelli, A Eggermont, WH Fridman, J Galon, C Sautès-Fridman, E Tartour, L Zitvogel, G Kroemer, Oncoimmunology 2012 1 699 716 10.4161/onci.20696 22934262
68. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. DE Spaner, Y Shi, D White, S Shaha, L He, A Masellis, K Wong, R Gorczynski, Leukemia 2010 24 222 226 10.1038/leu.2009.195 19759558
69. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Y Shi, D White, L He, RL Miller, DE Spaner, Cancer Res 2007 67 1823 1831 10.1158/0008-5472.CAN-06-2381 17308125